PBH Stock Forecast & Price Target

Prestige Consumer Healthcare has experienced an optimistic financial outlook, highlighted by a projected EBITDA increase of approximately $15 million for 2026 and 2027, driven by anticipated sales growth in its diverse brand portfolio. The company’s organic volume growth rate within Specialty Foods is expected to accelerate in the latter half of 2025, supported by significant product launches and enhanced capacity. Additionally, positive same-store sales growth in the U.S. and Canada signals improved consumer spending and operational performance, contributing to an overall positive assessment of revenue growth prospects.

Prestige Consumer Healthcare faces a negative outlook primarily due to potential revenue growth that may fall below expectations, compounded by EBITDA margin compression linked to persistent increases in input costs. The company is also at risk from a weakening operating environment in its main market of North America, which constitutes 85% of its total revenue, and from the performance trends of its largest customers. Furthermore, there are concerns about limited acquisition opportunities and the associated risks of integrating acquisitions, all of which contribute to uncertainty and potential downside in earnings.